Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality

Clinical Colorectal Cancer

Volumn 15, Issue 3, 2016, Pages 195-203

  Aran, Veronica ^a   Victorino, Ana Paula ^a   Thuler, Luiz Claudio ^a   Ferreira, Carlos Gil ^a,b  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b National Clinical Cancer Research Network (RNPCC) SCTIE MS   (Brazil)

Author keywords

Colorectal cancer incidence; Genetics; Prevention; Risk factors; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; INTERVENTION STUDY; LIFESTYLE; MALIGNANT TRANSFORMATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; COLORECTAL NEOPLASMS;

COLORECTAL NEOPLASMS; HUMANS; RISK FACTORS;

EID: 84959466627     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2016.02.008     Document Type: Review

References (123)

1. 1 Levine, J.S., Ahnen, D.J., Clinical practice. Adenomatous polyps of the colon. N Engl J Med 355 (2006), 2551–2557.
2. 2 Vogelstein, B., Fearon, E.R., Hamilton, S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988), 525–532.
3. 3 Paschos, K.A., Canovas, D., Bird, N.C., The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 21 (2009), 665–674.
4. 4 Ogino, S., Stampfer, M., Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 102 (2010), 365–367.
5. 5 Liao, X., Lochhead, P., Nishihara, R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367 (2012), 1596–1606.
6. 6 Ely, S., Personalized medicine: individualized care of cancer patients. Transl Res 154 (2009), 303–308.
7. 7 Ogino, S., Lochhead, P., Giovannucci, E., Meyerhardt, J.A., Fuchs, C.S., Chan, A.T., Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 33 (2014), 2949–2955.
8. 8 Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
9. 9 Bailey, C.E., Hu, C.Y., You, Y.N., et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 150 (2015), 17–22.
10. 10 Kohler, B.A., Ward, E., McCarthy, B.J., et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103 (2011), 714–736.
11. 11 Jemal, A., Thun, M.J., Ries, L.A., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100 (2008), 1672–1694.
12. 12 La Vecchia, C., Bosetti, C., Lucchini, F., et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 21 (2010), 1323–1360.
13. 13 INCA: Atlas de mortalidade por câncer, 2008 Available at: http://mortalidade.inca.gov.br/Mortalidade/ Accessed: October 10, 2015.
14. 14 Center, M.M., Jemal, A., Smith, R.A., Ward, E., Worldwide variations in colorectal cancer. CA Cancer J Clin 59 (2009), 366–378.
15. 15 Freedman, A.N., Slattery, M.L., Ballard-Barbash, R., et al. Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 27 (2009), 686–693.
16. 16 Johns, L.E., Houlston, R.S., A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 96 (2001), 2992–3003.
17. 17 Cottet, V., Pariente, A., Nalet, B., et al. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology 133 (2007), 1086–1092.
18. 18 Burt, R., Neklason, D.W., Genetic testing for inherited colon cancer. Gastroenterology 128 (2005), 1696–1716.
19. 19 Fearon, E.R., Molecular genetics of colorectal cancer. Ann Rev Pathol 6 (2011), 479–507.
20. 20 Steliarova-Foucher, E., O'Callaghan, M., Ferlay, J., et al. The European Cancer Observatory: a new data resource. Eur J Cancer 51 (2015), 1131–1143.
21. 21 Froggatt, N.J., Green, J., Brassett, C., et al. A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. J Med Genet 36 (1999), 97–102.
22. 22 Armaghany, T., Wilson, J.D., Chu, Q., Mills, G., Genetic alterations in colorectal cancer. Gastrointest Cancer Res 5 (2012), 19–27.
23. 23 Sarasqueta, A.F., Forte, G., Corver, W.E., et al. Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer. BMC Cancer, 13, 2013, 277.
24. 24 Rajagopalan, H., Lengauer, C., Aneuploidy and cancer. Nature 432 (2004), 338–341.
25. 25 Smith, G., Carey, F.A., Beattie, J., et al. Mutations in APC, Kirsten-ras, and p53–alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 99 (2002), 9433–9438.
26. 26 Fodde, R., Kuipers, J., Rosenberg, C., et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 3 (2001), 433–438.
27. 27 de la Chapelle, A., Hampel, H., Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28 (2010), 3380–3387.
28. 28 Boland, C.R., Goel, A., Microsatellite instability in colorectal cancer. Gastroenterology 138 (2010), 2073–2087.e3.
29. 29 Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J.G., Baylin, S.B., Issa, J.P., CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96 (1999), 8681–8686.
30. 30 Nazemalhosseini Mojarad, E., Kuppen, P.J., Aghdaei, H.A., Zali, M.R., The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench 6 (2013), 120–128.
31. 31 Lao, V.V., Grady, W.M., Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 8 (2011), 686–700.
32. 32 Geiersbach, K.B., Samowitz, W.S., Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 135 (2011), 1269–1277.
33. 33 Jass, J.R., Smith, M., Sialic acid and epithelial differentiation in colorectal polyps and cancer–a morphological, mucin and lectin histochemical study. Pathology 24 (1992), 233–242.
34. 34 Laiho, P., Kokko, A., Vanharanta, S., et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 26 (2007), 312–320.
35. 35 Yamane, L., Scapulatempo-Neto, C., Reis, R.M., Guimaraes, D.P., Serrated pathway in colorectal carcinogenesis. World J Gastroenterol 20 (2014), 2634–2640.
36. 36 Koinuma, K., Shitoh, K., Miyakura, Y., et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 108 (2004), 237–242.
37. 37 Leggett, B., Whitehall, V., Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 138 (2010), 2088–2100.
38. 38 Rustgi, A.K., BRAF: a driver of the serrated pathway in colon cancer. Cancer Cell 24 (2013), 1–2.
39. 39 Lubomierski, N., Plotz, G., Wormek, M., et al. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer 104 (2005), 952–961.
40. 40 Moran, A., Ortega, P., de Juan, C., et al. Differential colorectal carcinogenesis: molecular basis and clinical relevance. World J Gastrointest Oncol 2 (2010), 151–158.
41. 41 Qiu, L.X., Mao, C., Zhang, J., et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 46 (2010), 2781–2787.
42. 42 Gil Ferreira, C., Aran, V., Zalcberg-Renault, I., et al. KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. BMC Gastroenterol, 14, 2014, 73.
43. 43 Stefanius, K., Ylitalo, L., Tuomisto, A., et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology 58 (2011), 679–692.
44. 44 O'Brien, M.J., Yang, S., Mack, C., et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 30 (2006), 1491–1501.
45. 45 Irahara, N., Baba, Y., Nosho, K., et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 19 (2010), 157–163.
46. 46 Orlich, M.J., Singh, P.N., Sabate, J., et al. Vegetarian dietary patterns and the risk of colorectal cancers. JAMA Intern Med 175 (2015), 767–776.
47. 47 Key, T.J., Appleby, P.N., Crowe, F.L., Bradbury, K.E., Schmidt, J.A., Travis, R.C., Cancer in British vegetarians: updated analyses of 4998 incident cancers in a cohort of 32,491 meat eaters, 8612 fish eaters, 18,298 vegetarians, and 2246 vegans. Am J Clin Nutr 100:Suppl 1 (2014), 378S–385S.
48. 48 Lee, C.G., Hahn, S.J., Song, M.K., et al. Vegetarianism as a protective factor for colorectal adenoma and advanced adenoma in Asians. Dig Dis Sci 59 (2014), 1025–1035.
49. 49 Tantamango-Bartley, Y., Jaceldo-Siegl, K., Fan, J., Fraser, G., Vegetarian diets and the incidence of cancer in a low-risk population. Cancer Epidemiol Biomarkers Prev 22 (2013), 286–294.
50. 50 Zhu, B., Sun, Y., Qi, L., Zhong, R., Miao, X., Dietary legume consumption reduces risk of colorectal cancer: evidence from a meta-analysis of cohort studies. Sci Rep, 5, 2015, 8797.
51. 51 Gonzalez, C.A., Riboli, E., Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer 46 (2010), 2555–2562.
52. 52 Aune, D., Chan, D.S., Lau, R., et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ, 343, 2011, d6617.
53. 53 Alexander, D.D., Miller, A.J., Cushing, C.A., Lowe, K.A., Processed meat and colorectal cancer: a quantitative review of prospective epidemiologic studies. Eur J Cancer Prev 19 (2010), 328–341.
54. 54 Cross, A.J., Ferrucci, L.M., Risch, A., et al. A large prospective study of meat consumption and colorectal cancer risk: an investigation of potential mechanisms underlying this association. Cancer Res 70 (2010), 2406–2414.
55. 55 Raskov, H., Pommergaard, H.C., Burcharth, J., Rosenberg, J., Colorectal carcinogenesis–update and perspectives. World J Gastroenterol 20 (2014), 18151–18164.
56. 56 Shiels, M.S., Katki, H.A., Freedman, N.D., et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst, 106, 2014.
57. 57 Derry, M.M., Raina, K., Agarwal, C., Agarwal, R., Identifying molecular targets of lifestyle modifications in colon cancer prevention. Front Oncol, 3, 2013, 119.
58. 58 US Department of Health and Human Services. The health consequences of smoking—50 years of progress: A Report of the Surgeon General. 2014, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta.
59. 59 Botteri, E., Iodice, S., Bagnardi, V., Raimondi, S., Lowenfels, A.B., Maisonneuve, P., Smoking and colorectal cancer: a meta-analysis. JAMA 300 (2008), 2765–2778.
60. 60 Botteri, E., Iodice, S., Raimondi, S., Maisonneuve, P., Lowenfels, A.B., Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology 134 (2008), 388–395.
61. 61 Jensen, K., Afroze, S., Munshi, M.K., Guerrier, M., Glaser, S.S., Mechanisms for nicotine in the development and progression of gastrointestinal cancers. Transl Gastrointest Cancer 1 (2012), 81–87.
62. 62 Zhu, Y., Yang, S.R., Wang, P.P., et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer 110 (2014), 1359–1366.
63. 63 Liang, P.S., Chen, T.Y., Giovannucci, E., Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. Int J Cancer 124 (2009), 2406–2415.
64. 64 Yang, B., Jacobs, E.J., Gapstur, S.M., Stevens, V., Campbell, P.T., Active smoking and mortality among colorectal cancer survivors: the Cancer Prevention Study II Nutrition Cohort. J Clin Oncol 33 (2015), 885–893.
65. 65 Fedewa, S.A., Sauer, A.G., Siegel, R.L., Jemal, A., Prevalence of major risk factors and use of screening tests for cancer in the United States. Cancer Epidemiol Biomarkers Prev 24 (2015), 637–652.
66. 66 Walter, V., Jansen, L., Hoffmeister, M., Ulrich, A., Chang-Claude, J., Brenner, H., Smoking and survival of colorectal cancer patients: population-based study from Germany. Int J Cancer 137 (2015), 1433–1445.
67. 67 Chen, K., Xia, G., Zhang, C., Sun, Y., Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis. Int J Clin Exp Med 8 (2015), 3241–3257.
68. 68 Huxley, R.R., Ansary-Moghaddam, A., Clifton, P., Czernichow, S., Parr, C.L., Woodward, M., The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 125 (2009), 171–180.
69. 69 Rueda, M., Robertson, Y., Acott, A., et al. Association of tobacco and alcohol use with earlier development of colorectal pathology: should screening guidelines be modified to include these risk factors?. Am J Surg 204 (2012), 963–967 discussion: 967-8.
70. 70 Bardou, M., Montembault, S., Giraud, V., et al. Excessive alcohol consumption favours high risk polyp or colorectal cancer occurrence among patients with adenomas: a case control study. Gut 50 (2002), 38–42.
71. 71 Boffetta, P., Hashibe, M., Alcohol and cancer. Lancet Oncol 7 (2006), 149–156.
72. 72 Seitz, H.K., Becker, P., Alcohol metabolism and cancer risk. Alcohol Res Health 30 (2007), 38–41 44-7.
73. 73 Heit, C., Dong, H., Chen, Y., Shah, Y.M., Thompson, D.C., Vasiliou, V., Transgenic mouse models for alcohol metabolism, toxicity, and cancer. Adv Exp Med Biol 815 (2015), 375–387.
74. 74 Park, Y., Freedman, A.N., Gail, M.H., et al. Validation of a colorectal cancer risk prediction model among white patients age 50 years and older. J Clin Oncol 27 (2009), 694–698.
75. 75 Steffen, A., MacInnis, R.J., Joshy, G., Giles, G.G., Banks, E., Roder, D., Development and validation of a risk score predicting risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 23 (2014), 2543–2552.
76. 76 Isella, C., Terrasi, A., Bellomo, S.E., et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 47 (2015), 312–319.
77. 77 Calon, A., Lonardo, E., Berenguer-Llergo, A., et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 47 (2015), 320–329.
78. 78 Aalok Kumar, H.F.K., Lim, H.J., Renouf, D.J., Woods, R., Speers, C., Cheung, W.Y., British Columbia Cancer Agency, Vancouver, BC, Canada. Adjuvant chemotherapy (AC) use and outcomes in stage II colon cancer (CC) with and without poor prognostic features. 2012 ASCO Annual Meeting. J Clin Oncol, 30(suppl), 2012 Abstract 3527.
79. 79 Gray, R., Barnwell, J., McConkey, C., Hills, R.K., Williams, N.S., Kerr, D.J., Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 (2007), 2020–2029.
80. 80 Andre, T., Boni, C., Navarro, M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27 (2009), 3109–3116.
81. 81 Tournigand, C., Andre, T., Bonnetain, F., et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 30 (2012), 3353–3360.
82. 82 Sargent, D.J., Goldberg, R.M., Jacobson, S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345 (2001), 1091–1097.
83. 83 Sargent, D.J., Yothers, G., Tejpar, S., et al., ACCENT Collaborative Group; Mayo Clinic, Rochester, MN; National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, and University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA; University of Leuven, KUL, Leuven, Belgium; Brigham and Women's Hospital, Boston, MA; Mayo Clinic College of Medicine, Rochester, MN; Pitie-Salpetriere Hospital, Paris, France; Oncology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy; Mount Sinai Hospital, Toronto, ON, Canada; The University of Texas MD Anderson Cancer Center, Houston, TX; Institut Paoli-Calmettes, Marseille, France; NSABP, Pittsburgh, PA; NSABP, and Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Pittsburgh, PA; Swiss Group for Clinical Cancer Research, Bern, Switzerland; University Hospital Geneva, Geneva, Switzerland; Mayo Clinic, Jacksonville, FL. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): a pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. J Clin Oncol, 32, 2014, 5 (Abstract 3507).
84. 84 Alberts, S.R., Sargent, D.J., Nair, S., et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307 (2012), 1383–1393.
85. 85 Winer, E., Gralow, J., Diller, L., et al. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J Clin Oncol 27 (2009), 812–826.
86. 86 Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008), 1757–1765.
87. 87 Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67 (2007), 2643–2648.
88. 88 Van Cutsem, E., Kohne, C.H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009), 1408–1417.
89. 89 De Roock, W., Claes, B., Bernasconi, D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11 (2010), 753–762.
90. 90 Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., Bardelli, A., Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101 (2009), 1308–1324.
91. 91 Bokemeyer, C., Bondarenko, I., Makhson, A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27 (2009), 663–671.
92. 92 Amado, R.G., Wolf, M., Peeters, M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 1626–1634.
93. 93 Siddiqui, A.D., Piperdi, B., KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 17 (2010), 1168–1176.
94. 94 Allegra, C.J., Jessup, J.M., Somerfield, M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27 (2009), 2091–2096.
95. 95 Winder, T., Mundlein, A., Rhomberg, S., et al. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 21 (2009), 1283–1287.
96. 96 Al-Mulla, F., Milner-White, E.J., Going, J.J., Birnie, G.D., Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 187 (1999), 433–438.
97. 97 Andreyev, H.J., Norman, A.R., Cunningham, D., et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85 (2001), 692–696.
98. 98 Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J.R., Clarke, P.A., Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst 90 (1998), 675–684.
99. 99 Messner, I., Cadeddu, G., Huckenbeck, W., et al. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol 139 (2013), 201–209.
100. 100 Kumar, S.S., Price, T.J., Mohyieldin, O., Borg, M., Townsend, A., Hardingham, J.E., KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model. Gastrointest Cancer Res 7 (2014), 23–26.
101. 101 Ciardiello, F., Kohne, C., Lenz, H., et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol, 32, 2014, 5s (Abstract 3506).
102. 102 Maughan, T.S., Adams, R.A., Smith, C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377 (2011), 2103–2114.
103. 103 Tveit, K.M., Guren, T., Glimelius, B., et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 30 (2012), 1755–1762.
104. 104 Douillard, J.Y., Oliner, K.S., Siena, S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (2013), 1023–1034.
105. 105 Peeters, M., Price, T.J., Cervantes, A., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28 (2010), 4706–4713.
106. 106 Fuchs, C.S., Marshall, J., Mitchell, E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25 (2007), 4779–4786.
107. 107 Giantonio, B.J., Catalano, P.J., Meropol, N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007), 1539–1544.
108. 108 Van Cutsem, E., Tabernero, J., Lakomy, R., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30 (2012), 3499–3506.
109. 109 Venook, A.P., Lenz, H.J., Innocenti, F., et al., Cancer and Leukemia Group B (Alliance), SWOG, and ECOG; University of California, San Francisco, San Francisco, CA; Duke University, Durham, NC; USC Norris Comprehensive Cancer Center, Los Angeles, CA; The University of North Carolina at Chapel Hill, Chapel Hill, NC; Mayo Clinic, Rochester, MN; Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; Virginia Commonwealth University, Richmond, VA; Pritzker School of Medicine, The University of Chicago, Chicago, IL; Department of Medical Oncology, Yale University School of Medicine, New Haven, CT; Southeast Cancer Control Consortium, CCOP, Goldsboro, NC; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; American Society of Clinical Oncology, Alexandria, VA; Brigham and Women's Hospital, Boston, MA; SWOG and Oregon Health & Science University, Portland, OR. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC); 2014 ASCO Annual Meeting. J Clin Oncol, 32, 2014, 5s (Abstract LBA3).
110. 110 Grothey, A., Van Cutsem, E., Sobrero, A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
111. 111 Oikonomou, E., Koustas, E., Goulielmaki, M., Pintzas, A., BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 5 (2014), 11752–11777.
112. 112 Xu, Q., Xu, A.T., Zhu, M.M., Tong, J.L., Xu, X.T., Ran, Z.H., Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis 14 (2013), 409–416.
113. 113 Kushi, L.H., Doyle, C., McCullough, M., et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 62 (2012), 30–67.
114. 114 Larsson, S.C., Wolk, A., Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 86 (2007), 556–565.
115. 115 Danaei, G., Vander Hoorn, S., Lopez, A.D., Murray, C.J., Ezzati, M., Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366 (2005), 1784–1793.
116. 116 Calistri, D., Rengucci, C., Casadei Gardini, A., et al. Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals. Cancer Epidemiol Biomarkers Prev 19 (2010), 2647–2654.
117. 117 Goldstein, D.A., Shaib, W.L., Flowers, C.R., Costs and effectiveness of genomic testing in the management of colorectal cancer. Oncology (Williston Park) 29 (2015), 175–183.
118. 118 Song, B.P., Jain, S., Lin, S.Y., et al. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn 14 (2012), 112–119.
119. 119 Mullard, A., Alnylam dealt blow. Nat Biotechnol, 27, 2009, 213.
120. 120 Klabunde, C.N., Cronin, K.A., Breen, N., Waldron, W.R., Ambs, A.H., Nadel, M.R., Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev 20 (2011), 1611–1621.
121. 121 Zauber, A.G., The impact of screening on colorectal cancer mortality and incidence: has it really made a difference?. Dig Dis Sci 60 (2015), 681–691.
122. 122 Saito, H., Colorectal cancer screening using immunochemical faecal occult blood testing in Japan. J Med Screen 13:Suppl 1 (2006), S6–S7.
123. 123 Shin, H.R., Masuyer, E., Ferlay, J., Curado, M.P., Cancer in Asia - Incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac J Cancer Prev 11:Suppl 2 (2010), 11–16.